TELA Bio Receives FDA 510(k) Clearance for Liora, Its First In-House Resorbable Scaffold

TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on soft-tissue reconstruction, announced on October 5, 2026 that the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold. Liora is a fully resorbable surgical mesh for soft tissue reinforcement. It is also the first implant that the company fully developed in its ISO 8 certified cleanroom in Malvern, Pennsylvania.

A First for In-House Development

“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers,” said CEO Heather Getz.

According to the company, Liora will allow TELA Bio to expand its footprint in the soft tissue reconstruction market. Getz added that the product “expands the options available to surgeons and patients for their soft tissue reconstruction needs.” Next, TELA Bio plans to share more details on its third-quarter earnings call, which it expects to host in early November.

Where the Business Stood in the Second Quarter

For the second quarter, TELA Bio reported revenue of $19.3 million, down 4% from $20.2 million a year earlier. The company attributed the decline primarily to lower OviTex PRS volumes and price and mix headwinds, partially offset by growing international sales. At the same time, OviTex unit volume grew 12%, international revenue grew 26%, and LiquiFix revenue rose 39% year over year.

Gross margin improved to 72% from 70%, which the company tied primarily to a tariff refund and a lower charge for excess and obsolete inventory. Meanwhile, net loss widened to $11.3 million from $9.9 million, and cash and cash equivalents stood at $30.4 million on June 30. In addition, the company withdrew its full-year 2026 revenue guidance while Getz, who became CEO on August 4, assesses the business and its strategic direction.

Cost Reductions and Cash Runway

On August 31, TELA Bio announced a cost reduction initiative to lower annual operating expenses by approximately $17.0 million, or 18%. The savings come from a targeted headcount reduction of approximately 20% and the streamlining of external resources. As a result, the company expects the initiative to extend its cash runway into 2028.

TELA Bio also expects a one-time restructuring charge of approximately $1.5 million in the third quarter of 2026, primarily for severance and other employee-related costs. On the same day, Roberto Cuca stepped down as Chief Operating Officer and Chief Financial Officer. Even so, Getz said the company is preserving “our ability to invest in our core growth priorities and product innovation.”

Strategic Investment Summary

• FDA Clearance: TELA Bio, Inc. (NASDAQ: TELA) received FDA 510(k) clearance for Liora, a fully resorbable surgical mesh for soft tissue reinforcement.
• In-House Development: Liora is the company’s first fully resorbable synthetic product designed and produced in-house, at its ISO 8 certified cleanroom in Malvern.
• Second-Quarter Revenue: Revenue was $19.3 million, down 4% year over year, as lower OviTex PRS volumes outweighed 12% OviTex unit growth and 26% international growth.
• Guidance: The company withdrew its full-year 2026 revenue guidance in August under its new CEO.
• Cost Reduction: TELA Bio plans to cut annual operating expenses by about $17.0 million, or 18%, and expects the move to extend its cash runway into 2028.
• Next Update: Management plans to share more on Liora and the cost initiative during its third-quarter earnings call in early November.

Find out more about the latest corporate developments and financial reports at the TELA Bio investor portal.